Potential probiotic aquaculture microbiomes: detecting inhibition of the fish pathogen

***Vibrio anguillarum* by a complex algal community**

Dóra Smahajcsik, Line Roager, Mikael Lenz Strube, Sheng-Da Zhang, Lone Gram

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kgs.

Lyngby, Denmark

Running title: Probiotic algal microbiome inhibiting fish pathogen

Keywords: algal microbiome, probiotics, *Vibrio, Isochrysis galbana, Tetraselmis suecica,* aquaculture,

pathogen antagonism

Corresponding author: Lone Gram, gram@bio.dtu.dk, +45 23688295

ORCID numbers

Dóra Smahajcsik – 0000-0002-6103-7283

Line Roager – 0000-0002-7033-7309

Mikael Lenz Strube – 0000-0003-0905-5705

Sheng-Da Zhang – 0000-0002-2220-3904

Lone Gram – 0000-0002-1076-5723

ABSTRACT

Intensive fish rearing in aquaculture is challenged by infectious diseases. Although vaccines have been successfully developed for mature fish, alternative disease control measures are needed for fish larvae and juveniles, whose immune systems are not yet fully developed. Probiotics, typically isolated as pure cultures from aquaculture microbiomes, offer a promising alternative to antibiotics, with the potential to reduce antibiotic use and, consequently, the risk of antibiotic resistance. In this study, we developed an *in vitro* assay to evaluate the anti-pathogen efficacy of not only individual bacterial cultures but also of mixed algal microbiomes derived from the live-feed microalgae *Tetraselmis suecica* and *Isochrysis galbana*, based on the premise that natural microbiomes have inherently evolved to combat pathogens. This assay was used to compete a GFP-tagged *Vibrio anguillarum*, a key fish pathogen, against different microbial communities, allowing us to quantify the inhibitory activity through fluorescence. We found that the *Isochrysis galbana* microbiome was more inhibitory to *V. anguillarum* than the *Tetraselmis suecica* microbiome. During co-culture with the pathogen, the *Isochrysis* microbiomes increased in bacterial density and reduced in diversity as determined by metataxonomic analyses. The enriched inhibitory microbiomes could fully inhibit the pathogen. Bacteria isolated from these microbiomes were members of *Alteromonadaceae, Halomonadaceae, Rhodobacteraceae, Vibrionaceae, Flavobacteriaceae,* and *Erythrobacteraceae*. Although some strains individually inhibited the pathogen, enhanced inhibition was observed when *Sulfitobacter pontiacus* D3 and *Halomonas campaniensis* D2 were co-cultured, even though neither were inhibitory as monocultures. Thus, this study demonstrates that microbial communities derived from natural algal microbiomes can have anti-pathogen effects, suggesting their potential as aquaculture probiotics. Furthermore, the results indicate that bacterial co-cultures may offer synergistic advantages over monocultures, highlighting their promise for aquaculture health strategies.

IMPORTANCE

Aquaculture is the fastest growing food protein producing sector and sustainable disease control measures are required. Here we demonstrate that bacteria, single or mixed cultures, from algal microbiomes can inhibit the potent fish pathogen *Vibrio anguillarum*. We developed an assay, by GFP-tagging of a potent fish pathogen, allowing the anti-pathogen effect of a complex microbiome to be quantitatively determined. The microbiomes were derived from algae normally used in marine larviculture and directing these microbiomes in a disease suppressive direction can limit the use of antibiotics for disease control and reduce the risk of spread of antibiotic resistance.

INTRODUCTION

As the human population continues to rise, sustainable production of dietary protein is becoming increasingly important, and aquaculture is a key sector in supplying such high quality protein and has for decades been the fastest growing protein producing food sector (1). However, intensive rearing of fish carries with it the risk of disease outbreaks, which are especially damaging during larval development (1, 2) where disease outbreaks can result in substantial economic losses, as seen in a 1988 incident where vibriosis led to a 40% loss of juvenile turbot in a Norwegian hatchery (3, 4). Fish larvae lack a mature immune system, rendering vaccination ineffective as a control measure against disease (1, 2). *Vibrionaceae* infections pose a considerable challenge to marine larviculture and can be caused by a number of *Vibrio* species, including *V. anguillarum* that can infect up to 80 different fish species (5, 6). Despite advances in vaccine development, vibriosis remains a significant problem in aquaculture, primarily affecting marine fish and crustaceans (6, 7).

Many commercially valuable marine fish species require live feed, such as microalgae, at the larval stages since suitable artificial feed formulations are not available (8, 9), however, live feed can serve as the infection vector for pathogenic bacteria in larval rearing, leading to swift and widespread infections and complicating disease management (9, 10). Historically, antibiotics have been used to control these infections among larvae and juveniles, but since this may lead to spread of antimicrobial resistance (AMR) of both clinical and agri- and aquacultural relevance, alternative approaches are urgently needed (11). A promising strategy to mitigate bacterial pathogen proliferation in live feed and fish larvae is the use of probiotic bacteria which can inhibit pathogenic bacteria (12–14). Probiotic microorganisms, as defined by FAO and WHO, are "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host" (15). As reviewed in Sonnenschein *et al.* (16), probiotics can be an environmentally sustainable and economically viable approach to counteract economic losses due to bacterial pathogens in aquaculture, and have been intensively studied in the past decades (2, 17). Of special note are members of the *Phaeobacter* and *Ruegeria* genera which are particularly promising as probiotics in marine larviculture. The genera are part of the widely occurring marine *Roseobacter* group and they occur naturally in the aquaculture environment and produce a vibrio-antagonizing compound tropodithietic acid (TDA) (18). The TDA-producing roseobacters can protect fish larvae against vibriosis (12, 19, 20), and several studies have demonstrated that resistance does not develop (21, 22) likely due to the molecular effect of TDA as an antiporter (23).

As exemplified by the TDA-producing roseobacters, harnessing the potential of natural microbiomes for the use of probiotics is a promising approach for pathogen control in aquaculture. This method leverages the microbial communities found in aquatic ecosystems to protect and enhance the health of aquaculture organisms (16). Studies on probiotics have typically relied on the isolation and testing of pure bacterial cultures, however, in contrast to traditional single-isolate probiotics, complex microbiomes may offer a more holistic approach by capitalizing on the synergistic interactions among multiple microorganisms, including bacteria, to effectively combat pathogens (24). Several studies have focused on use of probiotics in larviculture and have suggested that deriving potential probiotic cultures from the aquaculture system offers an ecological advantage when they are re-introduced (12, 16, 25, 26).

Microalgae, such as *Tetraselmis suecica* and *Isochrysis galbana*, that are used as live feed in many larviculture productions are colonized by a microbiome, called the phycosphere, that can influence the growth and metabolism of the algae (27–29). The algal microbiome depends on the host species (30), is taxonomically diverse and harbours a large bioactive potential (31, 32). Roseobacters, including the TDA-producers, have repeatedly been isolated from microalgae (18, 26, 33, 34), however, they represent only a part of the algal microbiome where they co-exist with several other taxa. The microbial world is characterized by an intricate web of interactions, some of which are mediated by small molecules through which microorganisms exchange information with their neighbours, competitors, and hosts. These interactions shape the microbial community and its functionality, however, monocultures lack these interactions that are important for e.g. inducing expression of biosynthetic gene clusters producing bioactive compounds (35–37). We therefore hypothesize that the collective microalgal microbiome and not only pure cultures of roseobacters could serve to counteract invasion of aquaculture pathogens. Using a complex microbiome to inhibit a target bacterium, we hope to harvest the enhanced inhibitory properties promoted by the microbiome interactions.

Whilst the study of single culture inhibition is straight forward, the high throughput screening of pathogen inhibition by a complex microbiome is more challenging, and a prime purpose of the present study was to develop a simple screening assay that would allow us to determine the pathogen inhibition by a complex microbiome. Therefore, we developed an assay that allows for the measurement of the antibacterial effect of complex microbiomes and subsequently determined the composition of an inhibitory microalgal microbiome based on 16S rRNA gene amplicon sequencing. Additionally, we isolated bacterial strains for future use as mixed probiotic cultures.

MATERIALS AND METHODS

Bacterial and algal strains and culture conditions. The fish pathogen *Vibrio anguillarum* NB10 with a fluorescent tag (NB10_pNQFlaC4-gfp27) (38) (later referred to as *Vibrio anguillarum* NB10_gfp) was used as target bacterium in the inhibition assays. *Phaeobacter piscinae* S26 (26) was used as a known antagonist of *Vibrio* as a positive control for establishing the fluorescence-based screening assay. *P. piscinae* and *V. anguillarum* were stored at –80°C and routinely cultivated on Marine Agar (MA; Difco2216 BD) at 25°C or in Marine Broth (MB; Difco2216 BD) at 25°C and 200 rpm, supplemented with 4 µg/mL chloramphenicol in case of *V. anguillarum* NB10_gfp. All bacterial cultures were stored and cultivated similarly, including *V. anguillarum* NB10 wild type (WT), and bacterial isolates obtained from algal cultures and enriched inhibitory microbiomes (see below).

Xenic microalgal cultures of *Tetraselmis suecica* and *Isochrysis galbana* were provided by aquaculture industry partners. Axenic algae *Isochrysis galbana* CCMP 1323 and *Tetraselmis suecica* CCAP 66/4 were purchased from the Bigelow National Center for Marine Algae and Microbiota (NCMA) and the Culture Collection of Algae and Protozoa (CCAP), respectively, and their axenic status determined by plating on MA. The algae were cultured in f/2 medium without silicate (f/2 – Si; NCMA; (39, 40)) made with 3% Instant Ocean (IO; Aquarium Systems Inc., Sarrebourg, France) and cultivated at 18°C and constant illumination at ~50 µE m^{-2} s^{-1}. Cultures were maintained by continuous subculturing every 4 weeks, transferring 1% of the culture to 25 mL fresh medium.

Fluorescence-based screening assay for GFP-labelled target organism. *V. anguillarum* NB10_gfp was grown overnight as described above and a 10-fold serial dilution was prepared using MB as a diluent. 180 µL of the dilutions were distributed to the wells of a sterile, black 96-well microplate with flat, clear bottom (Perkin Elmer, 6005430) in technical triplicates. *V. anguillarum* NB10 WT was included as a negative control for the fluorescence measurement, and sterile medium as a no-growth negative control. Fluorescence and absorbance were measured on a BioTek Cytation™ 5 multi-mode microplate reader at 25°C with shaking (linear, continuous, 567 cpm). Measurements were taken every 20 minutes over 40 hours, measuring fluorescence (excitation: 485/15 nm, emission: 513/15 nm) and OD$_{600}$.

Fluorescence-based inhibition assay by *Phaeobacter piscinae* S26. *Phaeobacter piscinae* S26 was co-cultured with *V. anguillarum* NB10_gfp in the fluorescence-based inhibition assay. Overnight cultures of both bacteria were prepared, 10-fold serially diluted in sterile medium (MB) and 90 µL of each dilution of both bacterial cultures was loaded into sterile, black 96-well microplates allowing crossed combinations of the two strains at the different dilutions (total well-content of 180 µL).

Dilutions of *P. piscinae* S26 were included as a negative control for the fluorescence measurement,

and sterile medium as a no-growth negative control. Dilutions of *V. anguillarum* were included as a

positive control. Absorbance and fluorescence of the plates were measured as described above.

Before the experiment, bacterial counts were determined by 10-fold serial dilution and plating on

MA.

Inhibition of *V. anguillarum* by complex algal microbiomes. Microbiomes from two xenic

microalgae, *Tetraselmis suecica* and *Isochrysis galbana,* were co-cultured with *V. anguillarum*

NB10_gfp using the fluorescence-based screening assay (Figure 1). Samples from axenic algal

cultures were included as controls without microbiomes. Five algal cultures were tested in the assay

described above. This included the two axenic cultures (AXT: axenic *Tetraselmis*; AXI: axenic

Isochrysis), two xenic cultures of *Tetraselmis suecica* (NT) and *Isochrysis galbana* (NI) that had been

re-cultivated in the lab since 2019 and 2020, respectively, and a newly acquired (2023) *Isochrysis*

galbana culture (NNI) from an aquaculture collaborator. Cultures (200 mL) of the two microalgae,

both axenic and xenic, were prepared by inoculating 10% stock culture to fresh media and

incubating them at 18°C and constant illumination for five days reaching approx. 6 log algal cells mL^{-1}

^{1}. The *V. anguillarum* NB10_gfp strain was grown overnight, and algal and bacterial counts were

determined at the beginning of the experiment. Bacterial counts were determined by 10-fold serial

dilution and plating on MA. Plates were incubated for two days for *V. anguillarum* and for four days

for the bacterial counts from algal cultures. All CFU counts were log-transformed before further

statistical analyses. Algal cell counts were determined using microscopy and a Neubauer-improved

chamber. To determine if any pathogen inhibition was caused by the algae or by their microbiomes,

the xenic algal cultures were divided into two 100 mL fractions: the full culture (FC) with algal and

bacterial cells, and a filtered microbiome (FM) fraction, where algal cells were removed by filtering

(47-mm Ø, pore size 3-µm, mixed cellulose ester, Advantec A300A047A). Before filtering, the

cultures were vortexed vigorously to detach bacteria from the algal cells.

To increase the bacterial density (target ~ 7 – 8 log CFU mL^{-1}), 100 ml of algal cultures were

harvested (2,445 x g, 10 min, 20°C) and resuspended in 1 mL sterile 3% IO. 10-fold serial dilutions of

both up-concentrated algal fractions (FC and FM; 3% IO as diluent) and *Vibrio* cultures (MB as

diluent) were prepared, and loaded into sterile, black 96-well microplates. Combinations of dilutions

of the pathogen (target: 3 log CFU mL^{-1} and 5 log CFU mL^{-1}) and algal samples (10^{-1} to 10^{-5} dilutions)

were loaded. Algal cultures with no addition of the GFP tagged pathogen were included as negative

control for the fluorescence measurement, and sterile medium as a no-growth negative control.

Different dilutions of the pure culture of *V. anguillarum* NB10_gfp were included as a positive

control. Fluorescence and OD_{600} were measured as described above. FM samples were measured on

a different instrument (BioTek Synergy HTX) than all other samples, resulting in a different scale of

the fluorescence measurements. The overview of sample preparation and experimental setup are

summarized in Figure 1.

Characterizing the enriched inhibitory microbiomes. During the co-culture inhibition assay, the

bacterial density of the algal microbiomes was increased. Several dilutions of the algal microbiomes

inhibited growth of *V. anguillarum* in a "dose dependent" manner and in all co-cultures, the

bacterial density of the algal microbiomes increased. These microbiomes which caused suppression

of the pathogen will be referred to as enriched inhibitory microbiomes. DNA was extracted from a

selection of the wells taking samples from wells exhibiting a complete inhibition and wells allowing

only marginal growth of *V. anguillarum*. Also, samples were taken from no-growth negative controls

of the experiment, resulting in a total of 41 samples. Upon completion of the assay, the plates and

samples were stored at -80°C until further processing, and then thawed at 4°C and samples kept on

ice. 2 x 200 μL lysis buffer (400 mM NaCl, 750 sucrose, 20 mM EDTA, 50 mM Tris-HCl, 1 mg/mL

lysozyme [pH 8.5]) was added to the wells. The contents of the wells were then resuspended and

transferred to Eppendorf tubes and incubated at 37°C for 30 min. Proteinase K was added to a final

concentration of 100 mg/mL and sodium dodecyl sulphate (SDS) to a final concentration of 1%

vol/vol, and samples were then incubated overnight at 55°C, 300 rpm (41). The order of handling of

samples was then randomized before extraction. DNA extraction was done by the Promega Maxwell

16 using the Maxwell LEV Blood DNA Kit, and the quality and purity of the DNA were measured using

a DeNovix 439 DS-11+ spectrophotometer (DeNovix Inc., Wilmington, DE, USA) and confirmed by gel

electrophoresis.

The V3-V4 region of the 16S rRNA gene of all samples was amplified by PCR as described in

Roager *et al*. (2023), using the primer set 341f (59-CCTACGGGNGGCWGCAG-39) and 805r (59-

GACTACHVGGGTATCTAATCC-39) tagged with 30 unique octametric barcodes (Table S1). PCR

products were purified using Agencourt AMPure XP magnetic beads (0.8:1 bead volume to DNA

solution; Agencourt Bioscience Corporation, Beverly, MA, USA). Concentrations of the amplicons

were determined using a Qubit 2.0 Fluorometer with the high sensitivity (HS) assay kit (Qubit[TM]

dsDNA HS assay; Invitrogen by Thermo Fisher Scientific Inc., Eugene, OR, USA). Samples were pooled

in equimolar ratios before library preparation and sequencing on an Illumina NovaSeq 6000 platform

with paired-end 250-bp reads (Novogene; Cambridge, United Kingdom).

Analyses of sequencing data. Sequencing data analyses were performed using QIIME 2 version

2023.5 (42) and R version 4.2.1 (43). The raw reads were imported to QIIME2, demultiplexed, and

primers and barcodes were removed using the cutadapt demux-paired plugin (44). Reads were then

denoised and dereplicated using the DADA2 package (45) and an amplicon sequence variant (ASV)

table was created leaving out sequences shorter than 400bp. A phylogenetic tree was constructed

using MAFFT (46) and FastTree (47), via the phylogeny plugin. Alpha- and beta-diversity metrics were

computed using the diversity plugin (48) at an even sampling depth of 26,226. A classifier trained on

the Silva database 138 (49) and the specific primer sequences employed as mentioned above was

used for taxonomic classification of the reads via the feature-classifier plugin (50, 51). ASVs which

were either not assigned to a phylum, classified as chloroplasts/mitochondria or had a frequency <

10 were filtered out before further analysis in R. Two sterility controls were excluded from the

dataset before further analysis. QIIME 2 artifacts were imported to R v4.2.1 using the qiime2R

package (52) and analysis was continued in RStudio (53) with the tidyverse (54) package. For

multivariate analyses using the vegan package, the ASV table was normalized by square-root

transformation and Wisconsin standardization (55). PERMANOVA analysis was then performed using

the beta-group-significance function of Qiime2 and the adonis plugin (56) in R with 999

permutations to test significant differences in beta diversity as a function of source culture (NI and

NNI), degree of pathogen inhibition, microbiome dilution and sample fraction (FC and FM), based on

Bray-Curtis dissimilarities calculated using the normalized ASV table. The analysis was conducted

both on the complete dataset and on subsets divided by samples before and after the enrichment

assay. Interactive effects were included in the models but were removed due to lack of significance.

Isolation and identification of bacterial strains from *Isochrysis galbana* microbiomes. Culturable

bacterial isolates were obtained from a subset of the enriched inhibitory *I. galbana* microbiomes (NI

and NNI) analysed for their microbiome composition. Culture from wells where *V. anguillarum* was

inhibited by the microbiomes was serially diluted and plated on MA. Isolates were picked

representing colonies with different morphology. Also, strains were picked from the plating of the

algal culture before testing inhibition (native microbiome), resulting in a total of 64 bacterial isolates.

The strains were re-streaked for purity and glycerol stocks (20% v/v) were made and stored at -80°C.

The isolates were later identified by 16S rRNA gene amplification by colony PCR using universal

primers 27F and 1492R and subsequent Sanger sequencing by Macrogen (Amsterdam, Netherlands).

Sequencing results were compared against the NCBI nucleotide database using the BLASTn function

(57) to determine the putative bacterial taxa.

Inhibition of *V. anguillarum* by pure cultures and co-cultures of bacterial isolates. Antagonism of

pure cultures of the 64 bacterial isolates against *V. anguillarum* NB10_gfp was tested using an agar-

based assay (58) using 50 µL of culture to 50 ml of agar and spotting 5 µL of an overnight culture of

the isolates on the pathogen-embedded plates. Plates were incubated at 25°C and visually inspected

for clearing zones after 24 and 48 hours. In a similar manner, dual cultures of isolates from the

enriched inhibitory microbiome were spotted on embedded *Vibrio* and inspected for inhibition. Five

isolates were chosen for investigating co-culture effects as representatives of the five non-*Vibrio*

genera isolated from the enriched inhibitory *I. galbana* microbiomes (Table 2) with complete

inhibition of 5.3 log CFU mL^{-1} starting inoculum of *V. anguillarum*. The strains were grown in liquid

cultures (MB, 25°C, 200 rpm) for 24 hours and then mixed 1:1 in pairs. 10 µL of the mixtures were

spotted on the pathogen-embedded plates. The plates were incubated at 25°C and visually

inspected for clearing zones after 24 and 48 hours. Monocultures of the individual strains mixed 1:1

with MB were used as controls.

Whole genome sequencing, annotation and analysis. The five isolates selected for the co-culture

study were whole genome sequenced with Oxford Nanopore sequencing, using the GridION

platform. Genomic DNA was extracted from overnight cultures with the NucleoSpin® Tissue Mini kit

(Macherey-Nagel, 740952.5) protocol for bacteria, with three hours of incubation during pre-lysis.

The quality, purity, and concentration of the DNA was assessed as described for amplicon

sequencing. The library was prepared using the Rapid Barcoding Kit 24 V14 (SQK-RBK114.24). The

resulting reads were processed by the dragonflye pipeline (59). Briefly, adaptors were trimmed using

Porechop and reads smaller than 1000bp were removed with Nanoq. The genomes were then

assembled with Flye and polished with Medaka. The assemblies were then annotated with Bakta

v1.8.2 (60), and profiled for BGCs with antiSMASH 7.0 (61). Subsequently, the assembled genomes

were taxonomically classified using autoMLST (62).

Data availability. The sequencing data from the microbiome analysis and the assembled whole

genomes are available on the Sequencing Read Archive under BioProject ID PRJNA1150956.

RESULTS

Fluorescence-based inhibition assay for GFP-labelled *Vibrio anguillarum*. *V. anguillarum* NB10_gfp,

as expected, grew well in MB reaching an absorbance of 0.929 ± 0.003 at 600 nm (in 19 hours for 5.3

log CFU mL^{-1} starting inoculum). The starting inocula of *V. anguillarum* NB10_gfp ranged between

1.3 to 9.3 log CFU mL^{-1}. In pure culture, the growth of *V. anguillarum* could be followed by the

fluorescent signal indicating the same lag phase, growth rate and stationary phase entry as seen on

the OD_{600} measurements (Figure 2A and 2B). *V. anguillarum* was then co-cultured with a dilution

series of a known antagonist, *Phaeobacter piscinae* S26, to provide proof-of-concept that growth-

inhibition of the pathogen could be detected by measuring (lack of) fluorescence signal of a

fluorescently tagged target organism. The starting inocula of *P. piscinae* S26 ranged between 9.1 to

1.1 log CFU mL^{-1}. As expected, lower starting concentrations of *Vibrio* were more easily inhibited

than higher concentrations (data not shown) and, conversely, higher concentrations of *Phaeobacter*

were more inhibitory than lower concentrations (Figure 2C).

Anti-pathogen inhibitory effect of algal microbiomes on *Vibrio anguillarum*. To investigate the

inhibitory effect of their microbiomes on *V. anguillarum* NB10, dilutions of samples from cultures of

two xenic microalgae, *I. galbana* and *T. suecica,* were co-cultured with the GFP-tagged fish

pathogen*.* In the experiments, the starting inocula of *V. anguillarum* NB10_gfp was 3.1 ± 0.3 log CFU

mL^{-1} (target: 3 log CFU mL^{-1}) and 5.1 ± 0.3 log CFU mL^{-1} (target: 5 log CFU mL^{-1}). Initial algal cell

counts varied between 5.2 and 6.4 log cells mL^{-1} and up-concentration resulted in approx. 1.5 log

increase to between 7.2 and 8.0 log cells mL^{-1}. Initial bacterial counts in the *Isochrysis* samples varied

between 5.7 and 6.6 log CFU mL^{-1} and in the up-concentrated FC fraction between 7.6 and 8.4 log

CFU mL^{-1}, whereas in the up-concentrated FM fraction between 7.6 and 8.1 log CFU mL^{-1} (Table S2).

Microbiomes from both *T. suecica* and *I. galbana* inhibited growth of *V. anguillarum*, with the *I.*

galbana microbiome being more potent (Figure 3A vs. 3D and 3B vs. 3E). The same inhibition pattern

was observed for the filtered microbiomes (algal cells removed) as for the full culture (algal and

bacterial cells) (Figure 3A vs. 3B and 3D vs. 3E). No inhibition was observed from samples from

axenic algae cultures, indicating that it is indeed the microbiomes growing in the wells that inhibit

the pathogen (Figure 3C and 3F). OD_{600} measurements can be seen in Figure S1.

Sequence based analysis of microbiomes. In total, 70,542,064 paired end reads were obtained from

the 16S rRNA gene amplicons, with a mean of 1,500,894 reads per sample. After denoising, merging,

filtering out chloroplasts and mitochondria, removal of short sequences (< 400 bp) and low

abundant ASVs (total frequency < 10), this resulted in a total of 320 amplicon sequence variants

(ASVs), with a mean read count per sample of 209,507 (Table S3).

Microbiome composition and diversity analyses. The native microbiomes of *I. galbana* were

dominated by *Alteromonadaceae, Rhizobiaceae, Flavobacteriaceae, Rhodobacteraceae* and

Hyphomonadaceae. The microbiome composition of the two *I. galbana* cultures (NI and NNI)

differed significantly (PERMANOVA, R^2 = 0.312, p = 0.001), with NNI representing a relatively freshly

recruited microbiome and NI representing a selectively adapted microbiome, subcultured many

times in the laboratory over four years. The two cultures shared several genera, such as

Flavobacteriaceae, Rhizobiaceae, Alteromonadaceae and *Rhodobacteraceae*, but also had distinct

microbiome compositions. *Hyphomonadaceae* and *Cyclobacteriaceae* were unique to NI, and each

culture had several distinct representatives of *Flavobacteriaceae* and *Rhodobacteraceae* (Figure S2).

The enriched inhibitory microbiomes from the *Vibrio* inhibition assay were largely

dominated by *Alteromonadaceae* and *Rhodobacteraceae*, with a higher relative abundance of

Vibrionaceae compared to the native microbiome. As expected, the relative abundance of

Vibrionaceae was highest in samples with marginal growth of the pathogen, compared to those with

complete inhibition of the target pathogenic vibrio. However, *Vibrionaceae* were also detected in

lower relative abundances in enriched cultures that fully inhibited *V. anguillarum*, suggesting these

sequences could represent native vibrios of the algal microbiome. The relative abundances of

Alteromonadaceae and *Rhodobacteraceae* increased during the inhibition assay, whereas those of

Rhizobiaceae, *Flavobacteriaceae*, and *Hyphomonadaceae* decreased.

Community richness (Faith index), diversity (Shannon index), and evenness (Pielou's index)

showed no significant differences between microbiomes with different degree of pathogen

inhibition (p > 0.05). However, based on a pairwise Kruskal-Wallis analysis, significant differences in

Pielou's index were observed between the NI and NNI cultures (p = 0.0041), with the NI culture

having a higher diversity and evenness. PERMANOVA analysis of the full dataset indicated a

significant shift in microbial community composition from before (native microbiome) to after the

experiment (enriched inhibitory microbiome). Therefore, the data was split into two subsets for

further analysis.

Post-enrichment, community composition was significantly affected by the source culture

(NI vs. NNI) (PERMANOVA, R^2 = 0.253, p = 0.001), degree of pathogen inhibition (PERMANOVA, R^2 =

0.064, p = 0.017), microbiome dilution (PERMANOVA, R^2 = 0.098, p = 0.001), and algal fraction (full

culture (FC) vs. filtered microbiome (FM)) (PERMANOVA, R^2 = 0.060, p = 0.025). Residual variation

accounted for 52.5% of the total variation.

In conclusion, the degree of pathogen inhibition was associated with differences in the

taxonomic composition of the sampled microbiomes. However, most variation between

microbiomes was explained by differences between the two source cultures (NI and NNI.

Isolation and identification of bacterial strains from *Isochrysis galbana* microbiomes. A total of 64

isolates were obtained from *I. galbana* microbiomes either from the native algal culture (19 strains)

or from the enriched inhibitory microbiomes (45 strains) and tentatively identified using full-length

16S rRNA gene sequencing (Table S4). Strains from the native microbiome were identified as

members of the *Alteromonas* (2 isolates)*, Croceibacter* (1 isolate)*, Mameliella* (1 isolate)*,*

Phaeobacter (3 isolates)*, Qipengyuania* (3 isolates)*, Roseovarius* (2 isolates)*, Ruegeria* (1 isolate) and

Sulfitobacter (6 isolates) genera (Table 1), whereas strains from the enriched inhibitory microbiomes

were identified as members of the *Alteromonas* (5 isolates)*, Halomonas* (1 isolate)*, Phaeobacter* (18

isolates)*, Roseovarius* (7 isolates)*, Sulfitobacter* (11 isolates) and *Vibrio* (3 isolates) genera (Table 2).

Inhibition of *V. anguillarum* by pure cultures and co-cultures of isolates. Pure cultures of all 64

isolates were tested for their ability to inhibit *V. anguillarum* NB10 and 17 isolates with pronounced

inhibitory activity (zone of inhibition in the embedded pathogen) were all identified as *Phaeobacter*

sp. (Table 3, Figure S3). The dual co-cultures of representative isolates showed inhibition zones in all

co-cultures that included *Phaeobacter piscinae* (isolate H2). In some cases, the co-culture of *P.*

piscinae (isolate H2) and *Roseovarius* sp. (isolate C7) resulted in a larger clearing zone as compared

to the monoculture of the *P. piscinae*, however this result was not consistently reproducible. Of

special interest was the co-culture of *Sulfitobacter pontiacus* (isolate D3) and *Halomonas*

campaniensis (isolate D2), which despite showing only slight (*Halomonas campaniensis)* or no

(*Sulfitobacter pontiacus)* inhibition in single culture, were remarkably inhibitory when grown

together (Figure 4).

Whole genome sequencing and genome mining. The species identity of the five chosen isolates was

confirmed through Average Nucleotide Identity (ANI%) analysis: *Roseovarius nubinhibens* (isolate C7,

ANI 90.0%; referred to as *Roseovarius* sp.), *Halomonas campaniensis* (isolate D2, ANI 98.4%),

Sulfitobacter pontiacus (isolate D3, ANI 97.3%), *Alteromonas macleodii* (isolate E2, ANI 99.0%),

Phaeobacter piscinae (isolate H2, ANI 98.2%). Genome assembly of the sequencing data from the

five isolates yielded three closed genomes and two draft genomes (Table 4). According to

antiSMASH (61) analysis, *Halomonas campaniensis* D2 carries seven BGCs (NI-siderophore,

ranthipeptide, redox-cofactor, RIPP-like, T1PKS, betalactone, ectoine) and *Sulfitobacter pontiacus* D3

four BGCs (RiPP-like, betalactone, hserlactone, redox-cofactor), potentially encoding antibacterial

compounds.

DISCUSSION

The rapid spread of pathogenic bacteria within intensive aquaculture systems remains a significant

challenge, especially during the vulnerable larval development stage, and disease outbreaks often

results in substantial economic losses. In this study, we investigated the probiotic potential of the

microbiomes from two algae typically employed as live feed in marine larviculture, *Tetraselmis*

suecica and *Isochrysis galbana*. By identifying microbiomes with disease suppression, we aim to

provide a novel approach to disease control in aquaculture, reducing reliance on antibiotics and the

risk of spread of AMR.

Determining the inhibitory effect of a mixed microbiome against a particular pathogenic bacterium

requires specific detection and quantification of the pathogen. Previous works on fish pathogens

have used several approaches for determining inhibition in a mixed microbial population. For

instance tagging the pathogen with an antibiotic resistance marker enabling specific quantification

by culturing on antibiotic containing media (12, 25, 38), using semi-selective media and distinct

colony morphology in defined co-cultures (9, 63, 64), using flow cytometry to determine

concentrations of a GFP-tagged pathogen (25), or developing specific primers and designing a qPCR

approach has been a strategy for specific detection (9). Both the culturing approaches as well as the

qPCR method are labour-intensive and time-consuming. To enable a faster screen for pathogen-

inhibitory effect of a mixed microbial community, we used a GFP-tagged pathogen and

demonstrated that the fluorescent signal is a robust indication of growth of the pathogen, and that it

can be used to detect its inhibition by other microorganisms. Thus, we developed a robust

methodology for screening mixed microbiomes for their anti-pathogenic potential, thereby offering

a valuable tool for developing sustainable disease management strategies. This method facilitates

identifying microbiomes with the greatest potential for disease control, contributing to the

sustainable growth of aquaculture and the global effort to combat AMR.

We used the method to demonstrate that both the native, complete microbiomes and diluted

microbiomes of two microalgae used in aquacultures were able to inhibit the growth of fish

pathogen *Vibrio anguillarum* NB10. In contrast to findings from previous studies where cultures of

Isochrysis sp. and *Tetraselmis suecica* have themselves been inhibitory to fish pathogenic *Vibrio*

species (63–65), we did not find that *V. anguillarum* was inhibited by axenic *I. galbana* or *T. suecica*.

Thus, in our study, it was clearly the microorganisms associated with the algae that inhibited growth

of the pathogen, emphasizing the crucial role of microbial communities associated with live feed in

larviculture for disease control. These findings highlight the potential of harnessing natural microbial

consortia to enhance disease resistance in aquaculture settings.

Sequence-based analysis of *I. galbana* microbiomes found that *Rhizobiaceae*, *Alteromonadaceae*, and *Flavobacteriaceae* family members dominated the native *I. galbana* microbiome. This is in line with a number of previous studies reporting these families as members often found in the core microbiome of microalgae (66–69). The native microbiome also harboured members of the *Rhodobacteraceae*, which is a family commonly associated with microalgae and algal blooms (33, 66–69). The enriched inhibitory microbiomes were dominated by *Alteromonadaceae*, *Rhodobacteraceae*, and *Vibrionaceae* members, with decreased relative abundances of *Rhizobiaceae* and *Flavobacteriaceae* compared to the native microbiome. These shifts are likely heavily influenced by transferring the algal microbiome to a nutrient rich assay medium (MB) favouring fast-growing, heterotrophic bacteria. Interestingly, the degree of pathogen inhibition by the enriched inhibitory microbiomes is not explained by differences in the community richness, diversity, and evenness. However, it does correlate with distinct patterns in the overall community composition, suggesting that the inhibitory potential is influenced by the structure of the microbiome and synergistic interactions within a diverse community. Our findings also imply that complete pathogen inhibition can be achieved by a range of different enrichment cultures.

Pure cultures of *Phaeobacter piscinae* H2 isolated from the *I. galbana* microbiome inhibited *V. anguillarum* when tested in an agar-based assay, and this is consistent with numerous previous studies showing that several *Phaeobacter* species can inhibit *Vibrio* species (18, 20, 25, 26, 70). We anticipated this outcome also due to the distinctive brown colonies on MA agar, indicating the presence of the TDA-Fe complex, and thus the production of TDA, known for its antimicrobial effects (12, 16, 20, 71). Notably, all isolates that produced an inhibition zone of the embedded *V. anguillarum* were identified as *Phaeobacter* species, however, this genus was not among the ten most abundant genera of the enriched inhibitory microbiomes. This could indicate that instead of the potent antagonistic effect of particular genera, it may be a synergistic effect of the microbiome members that inhibits the pathogen.

The co-culture of *Sulfitobacter pontiacus* D3 and *Halomonas campaniensis* D2, isolated from the *I. galbana* microbiome, was inhibitory to *V. anguillarum* NB10, despite neither isolate showing pathogen inhibition as pure cultures. While it is beyond the scope of the current study to unravel the molecular and chemical mechanism underlying this co-culture-induced inhibition, previous research has demonstrated that biosynthetic gene clusters (BGCs) encoding antibiotic compounds can be elicited by co-cultivation of bacteria (35–37, 72). According to antiSMASH analyses, the genomes of

both bacteria harbour several BGCs. Therefore, future metabolomic analyses of the mono- and co-

cultures could provide insight into the co-culture-induced antimicrobial mechanism. Moreover,

several *Halomonas* species have been reported to produce an array of hydrolytic enzymes,

extracellular polysaccharides (EPS) (73), antibiotics (74), antifungals (75), and pigments (76).

Halomonas campaniensis D2, in particular, carries seven biosynthetic gene clusters potentially

encoding antibacterial compounds. This combined with the lack of inhibition by the monoculture

could suggest that the presence of *Sulfitobacter pontiacus* D3 may trigger the inhibitory effect.

Sulfitobacter species, often associated with marine algae and corals (77–79), possess the ability to

metabolize sulphite (80–82) and dimethylsulfoniopropionate (DMSP) (77). The breakdown of DMSP

produces potentially antimicrobial compounds such as acrylate (83, 84) and dimethyl sulphide

(DMS), which could indicate, that the sulphur metabolism capabilities of *Sulfitobacter* may

contribute to pathogen inhibition. Several *Sulfitobacter* species have also been reported to inhibit

fungal pathogens (85) and produce EPS (86), and extracellular cyclodipeptides (87).

Beiralas et. al reported that *Sulfitobacter pontiacus* is a key species of the *Emiliania huxleyi*

microbiome, protecting its algal host from bacterial pathogens even at low initial abundance (79).

While the mechanism of the algal protector phenotype was not determined, the authors suggest

that harbouring *Sulfitobacter* species in the algal microbiome presents the host with an advantage

and that *Sulfitobacter* species may play a key role in influencing population dynamics. Building on

these findings, we speculate that even a low abundance of *Sulfitobacter pontiacus* in a community or

co-culture may induce synergistic effects that enhance pathogen inhibition, potentially mediated

through the production of bioactive compounds. These insights highlight the importance of

microbial interactions in community functionality and stability.

In conclusion, by introducing an efficient methodology for screening mixed microbiomes, our study

offers a promising approach for identifying candidate microbiomes for sustainable disease

management. Our findings highlight the potential of harnessing natural microbial consortia to

enhance disease resistance in aquaculture and support the importance of microbial co-cultures as

potential disease control strategies.

ACKNOWLEDGEMENTS

We thank our aquaculture partners for providing algal cultures. This project has received funding from

the European Union's Horizon 2020 research and innovation programme under Grant Agreement no.

101000392 (MARBLES), the Novo Nordisk Foundation (NNF20OC0064249) and the Danish National

Research Foundation (DNRF137) for the Center for Microbial Secondary Metabolites. This output reflects only the author's view, and the Research Executive Agency (REA) cannot be held responsible for any use that may be made of the information contained therein. Figure 1 was created with BioRender.com.

REFERENCES

1. FAO. 2022. The State of World Fisheries and Aquaculture 2022. Towards Blue Transformation. FAO ; https://openknowledge.fao.org/handle/20.500.14283/cc0461en.

2. Ringø E, Olsen RE, Jensen I, Romero J, Lauzon HL. 2014. Application of vaccines and dietary supplements in aquaculture: possibilities and challenges. Rev Fish Biol Fish 24:1005–1032.

3. Westerdahl A, Olsson JC, Kjelleberg S, Conway PL. 1991. Isolation and characterization of turbot (*Scophtalmus maximus*)-associated bacteria with inhibitory effects against *Vibrio anguillarum*. Appl Environ Microbiol 57:2223–2228.

4. Ina-Salwany MY, Al-Saari N, Mohamad A, Mursidi F-A, Mohd-Aris A, Amal MNA, Kasai H, Mino S, Sawabe T, Zamri-Saad M. 2019. Vibriosis in Fish: A Review on Disease Development and Prevention. J Aquat Anim Health 31:3–22.

5. Frans I, Michiels CW, Bossier P, Willems KA, Lievens B, Rediers H. 2011. *Vibrio anguillarum* as a fish pathogen: virulence factors, diagnosis and prevention: Pathogen profile of *Vibrio anguillarum*. J Fish Dis 34:643–661.

6. Mohamad N, Amal MNA, Yasin ISM, Zamri Saad M, Nasruddin NS, Al-saari N, Mino S, Sawabe T. 2019. Vibriosis in cultured marine fishes: a review. Aquaculture 512:734289.

7. Tran L, Nunan L, Redman RM, Mohney LL, Pantoja CR, Fitzsimmons K, Lightner DV. 2013. Determination of the infectious nature of the agent of acute hepatopancreatic necrosis syndrome affecting penaeid shrimp. Dis Aquat Organ 105:45–55.

8. Hamre K, Yufera M, Rønnestad I, Boglione C, Conceição L, Izquierdo M. 2013. Fish larval

nutrition and feed formulation: Knowledge gaps and bottlenecks for advances in larval rearing.

Rev Aquac 5:S26–S58.

9. Rasmussen BB, Erner KE, Bentzon-Tilia M, Gram L. 2018. Effect of TDA-producing

Phaeobacter inhibens on the fish pathogen *Vibrio anguillarum* in non-axenic algae and copepod

systems. Microb Biotechnol 11:1070–1079.

10. Reid HI, Treasurer JW, Adam B, Birkbeck TH. 2009. Analysis of bacterial populations in the

gut of developing cod larvae and identification of *Vibrio logei*, *Vibrio anguillarum* and *Vibrio*

splendidus as pathogens of cod larvae. Aquaculture 288:36–43.

11. Dittmann KK, Rasmussen BB, Castex M, Gram L, Bentzon-Tilia M. 2017. The aquaculture

microbiome at the centre of business creation. Microb Biotechnol 10:1279–1282.

12. D'Alvise PW, Lillebø S, Prol-Garcia MJ, Wergeland HI, Nielsen KF, Bergh Ø, Gram L. 2012.

Phaeobacter gallaeciensis reduces *Vibrio anguillarum* in cultures of microalgae and rotifers,

and prevents vibriosis in cod larvae. PLoS ONE 7:e43996.

13. Gatesoupe FJ. 1999. The use of probiotics in aquaculture. Aquaculture 180:147–165.

14. Kesarcodi-Watson A, Kaspar H, Lategan MJ, Gibson L. 2008. Probiotics in aquaculture: The

need, principles and mechanisms of action and screening processes. Aquaculture 274:1–14.

15. Hotel A. 2001. Health and Nutritional Properties of Probiotics in Food Including Powder Milk

with Live Lactic Acid Bacteria – Joint FAO/WHO Expert Consultation 2014.

16. Sonnenschein EC, Jimenez G, Castex M, Gram L. 2021. The *Roseobacter* -Group Bacterium

Phaeobacter as a Safe Probiotic Solution for Aquaculture. Appl Environ Microbiol 87:e02581-

20.

17. Lieke T, Meinelt T, Hoseinifar SH, Pan B, Straus D, Steinberg C. 2019. Sustainable aquaculture

requires environmental-friendly treatment strategies for fish diseases. Rev Aquac 12:943–965.

18. Porsby CH, Nielsen KF, Gram L. 2008. *Phaeobacter* and *Ruegeria* Species of the *Roseobacter*

Clade Colonize Separate Niches in a Danish Turbot (*Scophthalmus maximus*)-Rearing Farm

and Antagonize *Vibrio anguillarum* under Different Growth Conditions. Appl Environ

Microbiol 74:7356–7364.

19. D'Alvise PW, Lillebø S, Wergeland HI, Gram L, Bergh Ø. 2013. Protection of cod larvae from

vibriosis by *Phaeobacter* spp.: A comparison of strains and introduction times. Aquaculture

384–387:82–86.

20. Planas M, Pérez-Lorenzo M, Hjelm M, Gram L, Uglenes Fiksdal I, Bergh Ø, Pintado J. 2006.

Probiotic effect in vivo of *Roseobacter* strain 27-4 against *Vibrio anguillarum* infections in

turbot (*Scophthalmus maximus* L.) larvae. Aquaculture 255:323–333.

21. Porsby CH, Webber MA, Nielsen KF, Piddock LJV, Gram L. 2011. Resistance and tolerance to

tropodithietic acid, an antimicrobial in aquaculture, is hard to select. Antimicrob Agents

Chemother 55:1332–1337.

22. Rasmussen BB, Grotkjær T, D'Alvise PW, Yin G, Zhang F, Bunk B, Spröer C, Bentzon-Tilia

M, Gram L. 2016. *Vibrio anguillarum* Is Genetically and Phenotypically Unaffected by Long-

Term Continuous Exposure to the Antibacterial Compound Tropodithietic Acid. Appl Environ

Microbiol 82:4802–4810.

23. Wilson MZ, Wang R, Gitai Z, Seyedsayamdost MR. 2016. Mode of action and resistance

studies unveil new roles for tropodithietic acid as an anticancer agent and the γ-glutamyl cycle

as a proton sink. Proc Natl Acad Sci 113:1630–1635.

24.   Timmerman HM, Koning CJM, Mulder L, Rombouts FM, Beynen AC. 2004. Monostrain,

567   multistrain and multispecies probiotics—A comparison of functionality and efficacy. Int J Food

568   Microbiol 96:219–233.

569   25.   Grotkjær T, Bentzon-Tilia M, D'Alvise P, Dierckens K, Bossier P, Gram L. 2016. *Phaeobacter*

570   *inhibens* as probiotic bacteria in non-axenic *Artemia* and algae cultures. Aquaculture 462:64–69.

571   26.   Grotkjær T, Bentzon-Tilia M, D'Alvise P, Dourala N, Nielsen KF, Gram L. 2016. Isolation of

572   TDA-producing *Phaeobacter* strains from sea bass larval rearing units and their probiotic effect

573   against pathogenic *Vibrio* spp. in *Artemia* cultures. Syst Appl Microbiol 39:180–188.

574   27.   Segev E, Wyche TP, Kim KH, Petersen J, Ellebrandt C, Vlamakis H, Barteneva N, Paulson JN,

575   Chai L, Clardy J, Kolter R. 2016. Dynamic metabolic exchange governs a marine algal-bacterial

576   interaction. eLife 5:e17473.

577   28.   Biondi N, Cheloni G, Rodolfi L, Viti C, Giovannetti L, Tredici MR. 2017. *Tetraselmis suecica*

578   F&M-M33 growth is influenced by its associated bacteria. Microb Biotechnol 11:211–223.

579   29.   Le Reun N, Bramucci A, Ajani P, Khalil A, Raina J-B, Seymour JR. 2023. Temporal variability

580   in the growth-enhancing effects of different bacteria within the microbiome of the diatom

581   *Actinocyclus* sp. Front Microbiol 14.

582   30.   Roager L, Kempen PJ, Bentzon-Tilia M, Sonnenschein EC, Gram L. 2023. Impact of host

583   species on assembly, composition, and functional profiles of phycosphere microbiomes. bioRxiv

584   https://doi.org/10.1101/2023.11.08.566273.

585   31.   Dittmann KK, Sonnenschein EC, Egan S, Gram L, Bentzon-Tilia M. 2019. Impact of

586   *Phaeobacter inhibens* on marine eukaryote-associated microbial communities. Environ

587   Microbiol Rep 11:401–413.

588   32.   Seyedsayamdost MR, Case RJ, Kolter R, Clardy J. 2011. The Jekyll-and-Hyde chemistry of

589   *Phaeobacter gallaeciensis*. 4. Nat Chem 3:331–335.

590   33.   González JM, Simó R, Massana R, Covert JS, Casamayor EO, Pedrós-Alió C, Moran MA.

591   2000. Bacterial community structure associated with a dimethylsulfoniopropionate-producing

592   North Atlantic algal bloom. Appl Environ Microbiol 66:4237–4246.

593   34.   Hahnke S, Brock NL, Zell C, Simon M, Dickschat JS, Brinkhoff T. 2013. Physiological

594   diversity of *Roseobacter* clade bacteria co-occurring during a phytoplankton bloom in the North

595   Sea. Syst Appl Microbiol 36:39–48.

596   35.   Moody SC. 2014. Microbial co-culture: harnessing intermicrobial signaling for the production

597   of novel antimicrobials. Future Microbiol 9:575–578.

598   36.   Scherlach K, Hertweck C. 2021. Mining and unearthing hidden biosynthetic potential. 1. Nat

599   Commun 12:3864.

600   37.   Selegato DM, Castro-Gamboa I. 2023. Enhancing chemical and biological diversity by co-

601   cultivation. Front Microbiol 14.

602   38.   Croxatto A, Lauritz J, Chen C, Milton DL. 2007. *Vibrio anguillarum* colonization of rainbow

603   trout integument requires a DNA locus involved in exopolysaccharide transport and

604   biosynthesis. Environ Microbiol 9:370–382.

605   39.   Guillard RRL. 1975. Culture of Phytoplankton for Feeding Marine Invertebrates, p. 29–60. *In*

606   Smith, WL, Chanley, MH (eds.), Culture of Marine Invertebrate Animals: Proceedings — 1st

607   Conference on Culture of Marine Invertebrate Animals Greenport. Springer US, Boston, MA.

608   40.   Guillard RRL, Ryther JH. 1962. Studies of marine planktonic diatoms: I. *Cyclotella nana*

609   Hustedt, and *Detonula confervacea* (cleve) Gran. Can J Microbiol 8:229–239.

610   41.   Boström KH, Simu K, Hagström Å, Riemann L. 2004. Optimization of DNA extraction for

611   quantitative marine bacterioplankton community analysis. Limnol Oceanogr Methods 2:365–

612   373.

42. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm

EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown

CT, Callahan BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Da Silva R, Diener C,

Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M,

Fouquier J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B,

Holmes S, Holste H, Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler

BD, Kang KB, Keefe CR, Keim P, Kelley ST, Knights D, Koester I, Kosciolek T, Kreps J,

Langille MGI, Lee J, Ley R, Liu Y-X, Loftfield E, Lozupone C, Maher M, Marotz C, Martin

BD, McDonald D, McIver LJ, Melnik AV, Metcalf JL, Morgan SC, Morton JT, Naimey AT,

Navas-Molina JA, Nothias LF, Orchanian SB, Pearson T, Peoples SL, Petras D, Preuss ML,

Pruesse E, Rasmussen LB, Rivers A, Robeson MS, Rosenthal P, Segata N, Shaffer M, Shiffer

A, Sinha R, Song SJ, Spear JR, Swafford AD, Thompson LR, Torres PJ, Trinh P, Tripathi A,

Turnbaugh PJ, Ul-Hasan S, van der Hooft JJJ, Vargas F, Vázquez-Baeza Y, Vogtmann E, von

Hippel M, Walters W, Wan Y, Wang M, Warren J, Weber KC, Williamson CHD, Willis AD,

Xu ZZ, Zaneveld JR, Zhang Y, Zhu Q, Knight R, Caporaso JG. 2019. Reproducible, interactive,

scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 37:852–857.

43. R Core Team. 2022. R: A Language and Environment for Statistical Computing. R Found Stat

Comput Vienna, Austria.

44. Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing reads.

1. EMBnet.journal 17:10–12.

45. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2:

High-resolution sample inference from Illumina amplicon data. Nat Methods 13:581–583.

46. Katoh K, Standley DM. 2013. MAFFT Multiple Sequence Alignment Software Version 7:

Improvements in Performance and Usability. Mol Biol Evol 30:772–780.

47.   Price MN, Dehal PS, Arkin AP. 2010. FastTree 2 – Approximately Maximum-Likelihood Trees

638   for Large Alignments. PLOS ONE 5:e9490.

639   48.   Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, Lozupone C, Zaneveld JR,

640   Vázquez-Baeza Y, Birmingham A, Hyde ER, Knight R. 2017. Normalization and microbial

641   differential abundance strategies depend upon data characteristics. Microbiome 5:27.

642   49.   Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Müller A,

643   Nothman J, Louppe G, Prettenhofer P, Weiss R, Dubourg V, Vanderplas J, Passos A,

644   Cournapeau D, Brucher M, Perrot M, Duchesnay É. 2018. Scikit-learn: Machine Learning in

645   Python. arXiv:1201.0490. arXiv https://doi.org/10.48550/arXiv.1201.0490.

646   50.   Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Gregory

647   Caporaso J. 2018. Optimizing taxonomic classification of marker-gene amplicon sequences with

648   QIIME 2's q2-feature-classifier plugin. Microbiome 6:90.

649   51.   Werner JJ, Koren O, Hugenholtz P, DeSantis TZ, Walters WA, Caporaso JG, Angenent LT,

650   Knight R, Ley RE. 2012. Impact of training sets on classification of high-throughput bacterial

651   16s rRNA gene surveys. ISME J 6:94–103.

652   52.   Bisanz JE. 2018. qiime2R: Importing QIIME2 artifacts and associated data into R sessions

653   (v0.99). HTML.

654   53.   RStudio Team. 2020. RStudio: Integrated Development Environment for R. RStudio PBC

655   Boston, MA.

656   54.   Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G, Hayes

657   A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J, Robinson

658   D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. 2019. Welcome

659   to the Tidyverse. J Open Source Softw 4:1686.

55.   Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin P, O'Hara B, Simpson G, Solymos P,

Stevens H, Wagner H. 2015. Vegan: Community Ecology Package. R Package Version 22-1

2:1–2.

56.   Anderson M. 2001. A new method for non-parametric multivariate analysis of variance. Austral

Ecol 26:32–46.

57.   Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009.

BLAST+: architecture and applications. BMC Bioinformatics 10:421.

58.   Gram L, Melchiorsen J, Bruhn JB. 2010. Antibacterial Activity of Marine Culturable Bacteria

Collected from a Global Sampling of Ocean Surface Waters and Surface Swabs of Marine

Organisms. Mar Biotechnol 12:439–451.

59.   Petit III RA. 2024. dragonflye: Assemble bacterial isolate genomes from Nanopore reads

(1.1.2). Perl.

60.   Schwengers O, Jelonek L, Dieckmann MA, Beyvers S, Blom J, Goesmann A. 2021. Bakta:

rapid & standardized annotation of bacterial genomes via alignment-free sequence identification

(1.9.3). Microb Genomics. Python.

61.   Blin K, Shaw S, Augustijn HE, Reitz ZL, Biermann F, Alanjary M, Fetter A, Terlouw BR,

Metcalf WW, Helfrich EJN, van Wezel GP, Medema MH, Weber T. 2023. antiSMASH 7.0:

new and improved predictions for detection, regulation, chemical structures and visualisation.

Nucleic Acids Res 51:W46–W50.

62.   Alanjary M, Steinke K, Ziemert N. 2019. AutoMLST: an automated web server for generating

multi-locus species trees highlighting natural product potential. Nucleic Acids Res 47:W276–

W282.

63.   Kokou F, Makridis P, Divanach P. 2012. Antibacterial activity in microalgae cultures. Aquac

Res 43:1520–1527.

64. Soto-Rodriguez SA, Magallón-Servín P, López-Vela M, Nieves Soto M. 2022. Inhibitory effect
of marine microalgae used in shrimp hatcheries on *Vibrio parahaemolyticus* responsible for
acute hepatopancreatic necrosis disease. Aquac Res 53:1337–1347.

65. Austin B, Baudet E, Stobie M. 1992. Inhibition of bacterial fish pathogens by *Tetraselmis*
suecica. J Fish Dis 15:55–61.

66. Roager L, Sonnenschein EC, Gram L. 2023. Sequence-Based Characterization of Microalgal
Microbiomes: Impact of DNA Extraction Protocol on Yield and Community Composition.
Microbiol Spectr 11:e03408-22.

67. Ahern OM, Whittaker KA, Williams TC, Hunt DE, Rynearson TA. 2021. Host genotype
structures the microbiome of a globally dispersed marine phytoplankton. Proc Natl Acad Sci
118:e2105207118.

68. Park BS, Choi W-J, Guo R, Kim H, Ki J-S. 2021. Changes in Free-Living and Particle-
Associated Bacterial Communities Depending on the Growth Phases of Marine Green Algae,
Tetraselmis suecica. 2. J Mar Sci Eng 9:171.

69. Steinrücken P, Jackson S, Müller O, Puntervoll P, Kleinegris D. 2023. A closer look into the
microbiome of microalgal cultures. Front Microbiol 14:1108018.

70. Roager L, Athena-Vasileiadi D, Gram L, Sonnenschein EC. 2024. Antagonistic activity of
Phaeobacter piscinae against the emerging fish pathogen *Vibrio crassostreae* in aquaculture
feed algae. Appl Environ Microbiol 90:e01439-23.

71. Brinkhoff T, Bach G, Heidorn T, Liang L, Schlingloff A, Simon M. 2004. Antibiotic Production
by a *Roseobacter* Clade-Affiliated Species from the German Wadden Sea and Its Antagonistic
Effects on Indigenous Isolates. Appl Environ Microbiol 70:2560–2565.

72. Zhuang L, Zhang H. 2021. Utilizing cross-species co-cultures for discovery of novel natural
products. Curr Opin Biotechnol 69:252–262.

73.   Biswas J, Jana SK, Mandal S. 2022. Biotechnological impacts of *Halomonas*: a promising cell

709   factory for industrially relevant biomolecules. Biotechnol Genet Eng Rev 1–30.

710   74.   Velmurugan S, Raman K, Thanga Viji V, Donio MBS, Adlin Jenifer J, Babu MM, Citarasu T.

711   2013. Screening and characterization of antimicrobial secondary metabolites from *Halomonas*

712   *salifodinae* MPM-TC and its *in vivo* antiviral influence on Indian white shrimp *Fenneropenaeus*

713   *indicus* against WSSV challenge. J King Saud Univ - Sci 25:181–190.

714   75.   Bibi F, Strobel GA, Naseer MI, Yasir M, Khalaf Al-Ghamdi AA, Azhar EI. 2018. Halophytes-

715   associated endophytic and rhizospheric bacteria: diversity, antagonism and metabolite

716   production. Biocontrol Sci Technol 28:192–213.

717   76.   Fariq A, Yasmin A, Jamil M. 2019. Production, characterization and antimicrobial activities of

718   bio-pigments by *Aquisalibacillus elongatus* MB592, *Salinicoccus sesuvii* MB597, and

719   *Halomonas aquamarina* MB598 isolated from Khewra Salt Range, Pakistan. Extremophiles

720   23:435–449.

721   77.   Lin S, Guo Y, Huang Z, Tang K, Wang X. 2023. Comparative Genomic Analysis of Cold-Water

722   Coral-Derived *Sulfitobacter faviae*: Insights into Their Habitat Adaptation and Metabolism. 5.

723   Mar Drugs 21:309.

724   78.   Wang C-N, Liu Y, Wang J, Du Z-J, Wang M-Y. 2021. *Sulfitobacter algicola* sp. nov., isolated

725   from green algae. Arch Microbiol 203:2351–2356.

726   79.   Beiralas R, Ozer N, Segev E. 2023. Abundant *Sulfitobacter* marine bacteria protect *Emiliania*

727   *huxleyi* algae from pathogenic bacteria. ISME Commun 3:100.

728   80.   Pukall R, Buntefuss D, Frühling A, Rohde M, Kroppenstedt R, Burghardt J, Lebaron P, Bernard

729   L, Stackebrandt E. 1999. *Sulfitobacter mediterraneus* sp. nov., a new sulfite-oxidizing member

730   of the *α-Proteobacteria*. Int J Syst Bacteriol 49 Pt 2:513–9.

81.   Ivanova EP, Gorshkova NM, Sawabe T, Zhukova NV, Hayashi K, Kurilenko VV, Alexeeva Y,

Buljan V, Nicolau DV, Mikhailov VV, Christen R. 2004. *Sulfitobacter delicatus* sp. nov. and

Sulfitobacter dubius sp. nov., respectively from a starfish (Stellaster equestris) and sea grass

(Zostera marina). Int J Syst Evol Microbiol 54:475–480.

82.   Sorokin D. 1995. *Sulfitobacter pontiacus* gen. nov., sp. nov. - A new heterotrophic bacterium

from the Black Sea, specialized on sulfite oxidation. Microbiology 64:295–305.

83.   Sieburth JM. 1960. Acrylic Acid, an "Antibiotic" Principle in Phaeocystis Blooms in Antarctic

Waters. Science 132:676–677.

84.   Raina J-B, Dinsdale EA, Willis BL, Bourne DG. 2010. Do the organic sulfur compounds DMSP

and DMS drive coral microbial associations? Trends Microbiol 18:101–108.

85.   Almeida JF, Marques M, Oliveira V, Egas C, Mil-Homens D, Viana R, Cleary DFR, Huang

YM, Fialho AM, Teixeira MC, Gomes NCM, Costa R, Keller-Costa T. 2023. Marine sponge

and octocoral-associated bacteria show versatile secondary metabolite biosynthesis potential and

antimicrobial activities against human pathogens. 1. Mar Drugs 21:34.

86.   Yang Q, Ge Y-M, Iqbal N, Yang X, Zhang X-L. 2021. *Sulfitobacter alexandrii* sp. nov., a new

microalgae growth-promoting bacterium with exopolysaccharides bioflocculanting potential

isolated from marine phycosphere. Antonie Van Leeuwenhoek 114.

87.   Long C, Lu X-L, Gao Y, Jiao B-H, Liu X-Y. 2011. Description of a *Sulfitobacter* Strain and Its

Extracellular Cyclodipeptides. Evid-Based Complement Altern Med ECAM 2011:393752.

88.   Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, Glöckner FO. 2013.

Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation

sequencing-based diversity studies. Nucleic Acids Res 41:e1.

 LEGENDS FOR TABLES AND FIGURES

Table 1. Identification (16S rRNA gene sequence and BLAST) of bacterial isolates from the native

Isochrysis galbana cultures.

Table 2. Identification (16S rRNA gene sequence and BLAST) of bacterial isolates from the enriched

inhibitory *Isochrysis galbana* cultures after co-culture with *Vibrio anguillarum*.

Table 3. Bacterial strains isolated from *Isochrysis galbana* cultures with the ability to inhibit *V.*

anguillarum. All isolates characterized by a clearing zone of different sizes (+, ++, +++) or a faint

clearing zone (*) were identified as *Phaeobacter* sp.

Table 4. Whole genome sequencing results of five bacterial isolates from the *Isochrysis galbana*

microbiome. Whole genome sequencing of *Roseovarius* sp. C7, *Halomonas campaniensis* D2,

Sulfitobacter pontiacus D3, *Alteromonas macleodii* E2, and *Phaeobacter piscinae* H2 yielded three

closed genomes and two draft genomes.

Figure 1. Yellow panels: Overview of algal cultures used in the *Vibrio* inhibition assays. Xenic cultures:

Tetraselmis suecica (NT) and *Isochrysis galbana* (NI – continuously subcultured, NNI – freshly recruited

microbiome). Axenic cultures: *T. suecica* (AxT) and *I. galbana* (AxI) with no microbiome (A). Sample

preparation: Xenic cultures were divided into Full culture (FC, containing algal and bacterial cells) and

Filtered microbiome (FM, algal cells removed by filtration) (B). All samples were 100-fold up-

concentrated, then 10-fold serial dilutions were co-cultured with *Vibrio anguillarum* NB10_gfp

(starting inoculum 10^3 or 10^5 CFU mL^{-1}) in a GFP-based inhibition assay (C). Teal panels: NI and NNI

samples indicated by DNA symbol were analysed through 16S rRNA gene amplicon sequencing (D).

Bacterial isolates from the native microbiome and the enriched inhibitory microbiome of *I. galbana*

(NI, NNI) were tested for inhibition of *V. anguillarum* in an agar-based assay (E).

Figure 2. *Vibrio anguillarum* NB10_gfp at different initial concentrations: 10^6 (●), 10^5 (□), 10^4 (▲), 10^3

(○) CFU mL^{-1}, as measured by (A) absorbance at 600 nm and by (B) fluorescence (GFP) using

excitation of 485/15 nm and emission of 513/15 nm, and the (C) inhibition profile of *V. anguillarum*

NB10_gfp (initial concentration: 10^4 CFU mL^{-1}) by antagonist *Phaeobacter piscinae* S26 at different

initial concentrations: 10^7 (△), 10^6 (●), 10^5 (□), 10^4 (▲), 10^3 (○), 10^2 (■) CFU mL^{-1}, as measured by

fluorescence (GFP, excitation: 485/15 nm, emission: 513/15 nm).

Figure 3. Inhibition by *Isochrysis galbana* (left) and *Tetraselmis suecica* (right) microbiomes of *Vibrio anguillarum* NB10_gfp (starting inoculum of 3.1 ± 0.3 log CFU mL^{-1}), as measured by fluorescence (GFP, excitation: 485/15 nm, emission: 513/15 nm). The inhibitory effect of serial dilutions (10^{-1} (△), 10^{-2} (●), 10^{-3} (□), 10^{-4} (▲), 10^{-5} (○)) of different fractions of the algal cultures have been tested: full culture (FC; 2A and 2D), with algal and bacterial cells; filtered microbiome (FM; 2B and 2E), where algal cells have been removed; and axenic (AX; 2C and 2F) cultures, where the algae cells are free of bacteria. FM samples were measured on a different instrument, hence a different scale of RFU.

Figure 4. Inhibition of *Vibrio anguillarum* NB10_gfp by co-cultures of bacterial species isolated from the enriched inhibitory *Isochrysis galbana* cultures, in an agar-based pathogen embedding assay. C7: *Roseovarius* sp., D2: *Halomonas campaniensis*, D3: *Sulfitobacter pontiacus*, E2: *Alteromonas macleodii*, H2: *Phaeobacter piscinae*.

Figure 5. Microbial composition (top 10 most abundant genera) of the native (left) and enriched inhibitory (right) microbiomes based on the 16S rRNA amplicon sequencing results. Samples from the enriched inhibitory microbiome are grouped by their inhibition profile: marginal growth of pathogen (*), medium inhibition of pathogen (**), full inhibition of pathogen (***).

Supplementary Tables and Figures

Table S1. List of thirty unique barcodes and primers used to amplify the V3-V4 region of the 16S rRNA gene in DNA from the microbiomes of *Isochrysis galbana* cultures. Primers and barcodes from (88).

Table S2. Algal and bacterial counts of different algal cultures (AXT, AXI, NT, NI and NNI) used in the *Vibrio* inhibition assay, before and after up-concentration ("Before" and "After"), and from different algal sample fractions (Full culture, FC and Filtered microbiome, FM). Counts are reported as mean ± standard deviation. In cases where standard deviation is not reported, data originated from unreplicated experimental conditions.

Table S3. DNA concentration after extraction, DNA amount provided for sequencing and number of sequences obtained from each sample (after denoising and filtering). Sample names indicate replicate ("R1", "R2") source culture ("NI", "NNI"), sample fraction (Full culture: "FC", Filtered microbiome:

"FM"), dilution factor of the algal microbiome (0 to -5), and starting inoculum of *V. anguillarum*

NB10_gfp ("V3", "V5" for 3 or 5 log CFU mL^{-1}) for samples obtained after the inhibition assay. The algal

cultures were sampled before up-concentrating and filtering ("raw", triplicates), and each fraction (FC

and FM) was sampled before the enrichment assay ("bf"). Sterile media controls were included ("MB-

ctrl").

Table S4. 64 bacterial strains isolated from the native ("Raw culture", 19 strains) or enriched inhibitory

("Full culture": FC, or "Filtered microbiome": FM, 45 strains) microbiome of *Isochrysis galbana*, and

tentatively identified using full-length 16S rRNA gene sequencing. The isolates originate from two

different *I. galbana* cultures (NI and NNI), acquired at different times from the same aquaculture unit.

Figure S1. Inhibition assay by *Isochrysis galbana* (left) and *Tetraselmis suecica* (right) microbiomes

against *Vibrio anguillarum* NB10_gfp, at a starting concentration of 3.1 ± 0.3 log CFU mL^{-1}, as measured

by absorbance at 600 nm. The inhibitory effect of serial dilutions (10^{-1} (△), 10^{-2} (●), 10^{-3} (□), 10^{-4} (▲), 10^{-5} (○)) of different fractions of the algal cultures have been tested: full culture (FC; S1A and S1D), with

algal and bacterial cells; filtered microbiome (FM; S1B and S1E), where algal cells have been removed;

and axenic (AX; S1C and S1F) cultures, where the algae cells are free of bacteria.

Figure S2. Native microbiome composition (top 10 most abundant genera) of two *Isochrysis galbana*

cultures of different age based on the 16S rRNA amplicon sequencing results. One culture, NNI has

been newly provided by an aquaculture facility and has a relatively freshly recruited microbiome

(left). The other culture, NI has been regularly subcultured under laboratory conditions for almost

four years (right).

Figure S3. Inhibition of *Vibrio anguillarum* NB10_gfp by 64 isolates from the *Isochrysis galbana*

microbiome. 16 isolates showed a clearing zone of varying size (all identified as *Phaeobacter* sp.),

and 13 isolates showed a faint halo, or a rough agar surface around the colony (identified as

Alteromonas, Sulfitobacter, Qipengyuania and *Croceibacter* sp.).

Table 1. Identification (16S rRNA gene sequence and BLAST) of bacterial isolates from the native *Isochrysis galbana* cultures.

Top BLAST hit (NCBI)	Genus	Family	Number of isolates	Present in enrichment culture
Alteromonas sp.	*Alteromonas*	*Alteromonadaceae*	2	Yes
Croceibacter sp.	*Croceibacter*	*Flavobacteriaceae*	1	No
Mameliella sp.	*Mameliella*	*Rhodobacteraceae*	1	No
Phaeobacter sp.	*Phaeobacter*	*Rhodobacteraceae*	3	Yes
Qipengyuania sp.	*Qipengyuania*	*Erythrobacteraceae*	3	No
Roseovarius nubinhibens	*Roseovarius*	*Rhodobacteraceae*	2	Yes
Ruegeria sp.	*Ruegeria*	*Rhodobacteraceae*	1	No
Sulfitobacter sp.	*Sulfitobacter*	*Rhodobacteraceae*	6	Yes

856   **Table 2.** Identification (16S rRNA gene sequence and BLAST) of bacterial isolates from the enriched inhibitory *Isochrysis galbana* cultures after

857   co-culture with *Vibrio anguillarum* NB10_gfp.

Top BLAST hit (NCBI)	Genus	Family	Number of isolates	In full (**) or marginally (*) inhibitory enrichments	
				**	*
Alteromonas sp.	*Alteromonas*	*Alteromonadaceae*	5	Yes	No
Halomonas alkaliphila	*Halomonas*	*Halomonadaceae*	1	Yes	No
Phaeobacter sp.	*Phaeobacter*	*Rhodobacteraceae*	18	Yes	Yes
Roseovarius nubinhibens	*Roseovarius*	*Rhodobacteraceae*	7	Yes	Yes
Sulfitobacter sp.	*Sulfitobacter*	*Rhodobacteraceae*	11	Yes	Yes
Vibrio sp.	*Vibrio*	*Vibrionaceae*	3	Yes	Yes

859 **Table 3.** Bacterial strains isolated from *Isochrysis galbana* cultures with the ability to inhibit *V.*

860 *anguillarum*. All isolates characterized by a clearing zone of different sizes (+, ++, +++) or a faint clearing

861 zone (*) were identified as *Phaeobacter* sp.

Isolate	Source	Best BLAST hit	ID%	Inhibition of *Vibrio anguillarum* NB10
B7	Raw culture, NI	*Phaeobacter piscinae*	99.57%	++
B9	Raw culture, NI	*Phaeobacter piscinae*	99.43%	+
C3	FC, NNI	*Phaeobacter piscinae*	99.43%	+
D4	FC, NNI	*Phaeobacter piscinae*	99.14%	+
D6	FC, NI	*Phaeobacter piscinae*	99.24%	+++
E4	FC, NI	*Phaeobacter piscinae*	99.42%	+++
E6	FC, NI	*Phaeobacter sp.* M8-4.3	98.24%	+++
E8	FC, NI	*Phaeobacter piscinae*	99.42%	++
E9	FC, NI	*Phaeobacter piscinae*	98.90%	+++
F3	FC, NI	*Phaeobacter sp.* M8-4.3	98.07%	++
F6	FM, NNI	*Phaeobacter piscinae*	98.72%	+
H2	FM, NI	*Phaeobacter piscinae*	98.96%	+++
H3	FM, NI	*Phaeobacter piscinae*	99.33%	*
H8	FM, NI	*Phaeobacter piscinae*	99.33%	++
I1	FM, NI	*Phaeobacter piscinae*	99.14%	+
I2	FM, NI	*Phaeobacter piscinae*	99.04%	++
I3	FM, NI	*Phaeobacter piscinae*	99.24%	+++

872   **Table 4.** Whole genome sequencing results of five bacterial isolates from the *Isochrysis galbana*

873   microbiome. Whole genome sequencing of *Roseovarius* sp. C7, *Halomonas campaniensis* D2, *Sulfitobacter*

874   *pontiacus* D3, *Alteromonas macleodii* E2, and *Phaeobacter piscinae* H2 yielded three closed genomes and

875   two draft genomes.

Isolate	Total genome length (bp)	N50 (bp)	Number of contigs	GC content (%)	Status of genome
Roseovarius sp. C7	3,819,388	3,578,952	6	62.9	Closed
Halomonas campaniensis D2	4,408,683	4,359,254	3	52.8	Closed
Alteromonas macleodii E2	5,090,176	4,653,070	3	44.5	Closed
Sulfitobacter pontiacus D3	3,995,328	279,876	45	60.2	Draft
Phaeobacter piscinae H2	3,981,236	909,707	11	60.2	Draft

Figure 1. Yellow panels: Overview of algal cultures used in the *Vibrio* inhibition assays. Xenic cultures: *Tetraselmis suecica* (NT) and *Isochrysis galbana* (NI – continuously subcultured, NNI – freshly recruited microbiome). Axenic cultures: *T. suecica* (AxT) and *I. galbana* (AxI) with no microbiome (A). Sample preparation: Xenic cultures were divided into Full culture (FC, containing algal and bacterial cells) and Filtered microbiome (FM, algal cells removed by filtration) (B). All samples were 100-fold up-concentrated, then 10-fold serial dilutions were co-cultured with *Vibrio anguillarum* NB10_gfp (starting inoculum 10^3 or 10^5 CFU mL^{-1}) in a GFP-based inhibition assay (C). Teal panels: NI and NNI samples indicated by DNA symbol were analysed through 16S rRNA gene amplicon sequencing (D). Bacterial isolates from the native

microbiome and the enriched inhibitory microbiome of *I. galbana* (NI, NNI) were tested for inhibition of

V. anguillarum in an agar-based assay (E).

Figure 2. *Vibrio anguillarum* NB10_gfp at different initial concentrations: 10^6 (●), 10^5 (□), 10^4 (▲), 10^3 (○)

CFU mL^{-1}, as measured by (A) absorbance at 600 nm and by (B) fluorescence (GFP) using excitation of

485/15 nm and emission of 513/15 nm, and the (C) inhibition profile of *V. anguillarum* NB10_gfp

(starting inoculum: 10^4 CFU mL^{-1}) by antagonist *Phaeobacter piscinae* S26 at different initial

concentrations: 10^7 (△), 10^6 (●), 10^5 (□), 10^4 (▲), 10^3 (○), 10^2 (■) CFU mL^{-1}, as measured by fluorescence

(GFP, excitation: 485/15 nm, emission: 513/15 nm).

Figure 3. Inhibition by *Isochrysis galbana* (left) and *Tetraselmis suecica* (right) microbiomes of *Vibrio*
anguillarum NB10_gfp (starting inoculum of 3.1 ± 0.3 log CFU mL^{-1}), as measured by fluorescence (GFP,
excitation: 485/15 nm, emission: 513/15 nm). The inhibitory effect of serial dilutions (10^{-1} (△), 10^{-2} (●), 10^{-3} (□), 10^{-4} (▲), 10^{-5} (○)) of different fractions of the algal cultures have been tested: full culture (FC; 2A and
2D), with algal and bacterial cells; filtered microbiome (FM; 2B and 2E), where algal cells have been
removed; and axenic (AX; 2C and 2F) cultures, where the algae cells are free of bacteria. FM samples were
measured on a different instrument, hence a different scale of RFU.

Figure 4. Inhibition of *Vibrio anguillarum* NB10_gfp by co-cultures of bacterial species isolated from the

enriched inhibitory *Isochrysis galbana* cultures, in an agar-based pathogen embedding assay. C7:

Roseovarius sp., D2: *Halomonas campaniensis*, D3: *Sulfitobacter pontiacus*, E2: *Alteromonas macleodii*,

H2: *Phaeobacter piscinae*.

Figure 5. Microbial composition (top 10 most abundant genera) of the native (left) and enriched inhibitory (right) microbiomes based on the 16S

rRNA amplicon sequencing results. Samples from the enriched inhibitory microbiome are grouped by their inhibition profile: marginal growth of

pathogen (*), medium inhibition of pathogen (**), full inhibition of pathogen (***).

Table S1. List of thirty unique barcodes and primers used to amplify the V3-V4 region of the 16S rRNA

gene in DNA from the microbiomes of *Isochrysis galbana* cultures. Primers and barcodes from (88).

Barcode no.	Barcode	Forward primer (with barcode)	Reverse primer (with barcode)
1	TTTTAATC	TTTTAATCCCTACGGGNGGCWGCAG	TTTTAATCGACTACHVGGGTATCTAATCC
2	ATAATTAG	ATAATTAGCCTACGGGNGGCWGCAG	ATAATTAGGACTACHVGGGTATCTAATCC
3	ACCAAATT	ACCAAATTCCTACGGGNGGCWGCAG	ACCAAATTGACTACHVGGGTATCTAATCC
4	CTTATCAA	CTTATCAACCTACGGGNGGCWGCAG	CTTATCAAGACTACHVGGGTATCTAATCC
5	TGATCATT	TGATCATTCCTACGGGNGGCWGCAG	TGATCATTGACTACHVGGGTATCTAATCC
6	AGAATCTA	AGAATCTACCTACGGGNGGCWGCAG	AGAATCTAGACTACHVGGGTATCTAATCC
7	TCAAGAAA	TCAAGAAACCTACGGGNGGCWGCAG	TCAAGAAAGACTACHVGGGTATCTAATCC
8	ATCGAAAT	ATCGAAATCCTACGGGNGGCWGCAG	ATCGAAATGACTACHVGGGTATCTAATCC
9	ACATTTAC	ACATTTACCCTACGGGNGGCWGCAG	ACATTTACGACTACHVGGGTATCTAATCC
10	TAGAAAAC	TAGAAAACCCTACGGGNGGCWGCAG	TAGAAAACGACTACHVGGGTATCTAATCC
11	TTATCACC	TTATCACCCCTACGGGNGGCWGCAG	TTATCACCGACTACHVGGGTATCTAATCC
12	AATAGGGT	AATAGGGTCCTACGGGNGGCWGCAG	AATAGGGTGACTACHVGGGTATCTAATCC
13	ATTGCTGA	ATTGCTGACCTACGGGNGGCWGCAG	ATTGCTGAGACTACHVGGGTATCTAATCC
14	TGAGTTCT	TGAGTTCTCCTACGGGNGGCWGCAG	TGAGTTCTGACTACHVGGGTATCTAATCC
15	GGCTATTT	GGCTATTTCCTACGGGNGGCWGCAG	GGCTATTTGACTACHVGGGTATCTAATCC
16	CAAGAGAT	CAAGAGATCCTACGGGNGGCWGCAG	CAAGAGATGACTACHVGGGTATCTAATCC
17	GGAATACA	GGAATACACCTACGGGNGGCWGCAG	GGAATACAGACTACHVGGGTATCTAATCC
18	AAGGCAAT	AAGGCAATCCTACGGGNGGCWGCAG	AAGGCAATGACTACHVGGGTATCTAATCC
19	ACAAAACG	ACAAAACGCCTACGGGNGGCWGCAG	ACAAAACGGACTACHVGGGTATCTAATCC
21	TTGAGTGA	TTGAGTGACCTACGGGNGGCWGCAG	TTGAGTGAGACTACHVGGGTATCTAATCC
22	GCTTCTGA	GCTTCTGACCTACGGGNGGCWGCAG	GCTTCTGAGACTACHVGGGTATCTAATCC
23	GGCAAGAT	GGCAAGATCCTACGGGNGGCWGCAG	GGCAAGATGACTACHVGGGTATCTAATCC
24	GTGCTTTC	GTGCTTTCCCTACGGGNGGCWGCAG	GTGCTTTCGACTACHVGGGTATCTAATCC
25	ACACACTG	ACACACTGCCTACGGGNGGCWGCAG	ACACACTGGACTACHVGGGTATCTAATCC
26	CGATTCTG	CGATTCTGCCTACGGGNGGCWGCAG	CGATTCTGGACTACHVGGGTATCTAATCC
27	GCAGAGTT	GCAGAGTTCCTACGGGNGGCWGCAG	GCAGAGTTGACTACHVGGGTATCTAATCC
30	GCTTGGTT	GCTTGGTTCCTACGGGNGGCWGCAG	GCTTGGTTGACTACHVGGGTATCTAATCC
31	ACAGGCTT	ACAGGCTTCCTACGGGNGGCWGCAG	ACAGGCTTGACTACHVGGGTATCTAATCC
40	GAGAGGGA	GAGAGGGACCTACGGGNGGCWGCA	GAGAGGGAGACTACHVGGGTATCTAATCC

922 **Table S2.** Algal and bacterial counts of different algal cultures (AXT, AXI, NT, NI and NNI) used in the

923 *Vibrio* inhibition assay, before and after up-concentration ("Before" and "After"), and from different

924 algal sample fractions (Full culture, FC and Filtered microbiome, FM). Counts are reported as mean ±

925 standard deviation. In cases where standard deviation is not reported, data originated from

926 unreplicated experimental conditions.

Algal culture	Algal counts (log cells/mL)		Bacterial counts (log CFU/mL)		
	Before	After	Before	After, FC	After, FM
AXT	5.2	7.2	N/A	N/A	N/A
AXI	5.9	7.2	N/A	N/A	N/A
NT	5.7	7.4	6.6	8.4	8.1
NI	6.4 ± 0.1	8.0 ± 0.1	6.0 ± 0.3	7.6 ± 0.2	7.8 ± 0.2
NNI	6.2 ± 0.6	7.5 ± 0.4	5.7 ± 0.6	7.7 ± 0.4	7.6 ± 0.3

Table S3. DNA concentration after extraction, DNA amount provided for sequencing and number of

sequences obtained from each sample (after denoising and filtering). Sample names indicate replicate

("R1", "R2"), source culture ("NI", "NNI"), sample fraction (Full culture: "FC", Filtered microbiome:

"FM"), dilution factor of the algal microbiome (0 to -5), and starting inoculum of *V. anguillarum*

NB10_gfp ("V3", "V5" for 3 or 5 log CFU mL^{-1}) for samples obtained after the inhibition assay. The algal

cultures were sampled before up-concentrating and filtering ("raw", triplicates), and each fraction (FC

and FM) was sampled before the enrichment assay ("bf"). Sterile media controls were included ("MB-

ctrl").

Sample name	DNA concentration after extraction (ng/µL)	Amount of DNA provided for sequencing (ng)	Number of sequences obtained
R1-NNI-FC_0_V5	43.2	250	172,237
R1-NNI-FC_-3_V5	60.8	250	659,903
R1-NNI-FC_-4_V5	54.8	250	141,745
R1-NNI-FC_-5_V3	36.8	250	125,582
R1-NNI-FC_bf	33.2	250	42,434
R1-NNI-FM_0_V5	100	250	37,770
R1-NNI-FM_-2_V5	66.4	250	283,545

R1-NNI-FM_-3_V5	47.8	250	211,372
R1-NNI-FM_-3_V3	77.6	250	422,921
R1-NNI-FM_-4_V3	112	250	275,217
R1-NNI-FM_bf	4.1	192,7	175,885
R1-NNI-MB-ctrl	0.834	39,198	11,352
R1-NNI-raw1	55.4	250	162,772
R1-NNI-raw2	85.4	250	54,564
R1-NNI-raw3	71.6	250	40,223
R2-NNI-FC_0_V5	58.4	250	75,491
R2-NNI-FC_-1_V5	39	250	550,497
R2-NNI-FC_-3_V3	95.4	250	106,340
R2-NNI-FC_-5_V3	73.4	250	324,687
R2-NNI-FC_bf	85	250	62,636
R2-NNI-FM_0_V5	75.4	250	238,018
R2-NNI-FM_-3_V3	120	250	162,818
R2-NNI-FM_-4_V3	48	250	294,405
R2-NNI-FM_bf	17.3	250	145,227
R2-NNI-raw1	43.4	250	25,781
R2-NNI-raw2	72.4	250	49,342
R2-NNI-raw3	72.8	250	74,725
R2-NI-FC_0_V5	81.2	250	291,271
R2-NI-FC_-2_V5	16.2	250	391,227
R2-NI-FC_-3_V3	61.6	250	297,668
R2-NI-FC_-4_V3	74.4	250	224,317
R2-NI-FC_bf	120	250	33,188
R2-NI-FM_0_V5	95.2	250	474,932
R2-NI-FM_-1_V5	61	250	265,940
R2-NI-FM_-2_V3	75	250	229,292
R2-NI-FM_-4_V3	50	250	226,214
R2-NI-FM_bf	16.4	250	367,349
R2-NI-MB-ctrl	1.98	93,06	39,985
R2-NI-raw1	86.8	250	43,457
R2-NI-raw2	92.2	250	169,394

Isolate	Source	Best BLAST hit	Query Cover	E value	ID%
	R2-NI-raw3	73.4	250		409,195

Table S4. 64 bacterial strains isolated from the native („Raw culture", 19 strains) or enriched inhibitory („Full culture": FC, or „Filtered microbiome": FM, 45 strains) microbiome of *Isochrysis galbana*, and tentatively identified using full-length 16S rRNA gene sequencing. The isolates originate from two different *I. galbana* cultures (NI and NNI), acquired at different times from the same aquaculture unit.

Isolate	Source	Best BLAST hit	Query Cover	E value	ID%
A1	Raw culture, NNI	*Alteromonas marina*	99%	0.0	98.14%
A2	Raw culture, NNI	*Sulfitobacter pacificus*	99%	0.0	99.17%
A3	Raw culture, NNI	*Roseovarius nubinhibens*	99%	0.0	98.61%
A4	Raw culture, NNI	*Roseovarius nubinhibens*	100%	0.0	98.88%
A5	Raw culture, NNI	*Sulfitobacter* sp.	100%	0.0	98.63%
A6	Raw culture, NNI	*Sulfitobacter pacificus*	100%	0.0	99.71%
A7	Raw culture, NNI	*Qipengyuania nanhaisediminis*	100%	0.0	99.54%
A8	Raw culture, NNI	*Qipengyuania aquimaris*	99%	0.0	98.90%
A9	Raw culture, NNI	*Ruegeria* sp.	100%	0.0	98.29%
B1	Raw culture, NNI	*Alteromonas macleodii*	100%	0.0	97.96%
B2	Raw culture, NNI	*Qipengyuania xiamenensis*	99%	0.0	99.56%
B3	Raw culture, NI	*Croceibacter* sp.	100%	0.0	99.22%
B4	Raw culture, NI	*Mameliella alba*	99%	0.0	98.43%
B5	Raw culture, NI	*Sulfitobacter* sp. LZD014	99%	0.0	99.34%
B6	Raw culture, NI	*Sulfitobacter* sp.	100%	0.0	98.82%
B7	Raw culture, NI	*Phaeobacter piscinae*	100%	0.0	99.57%
B9	Raw culture, NI	*Phaeobacter piscinae*	99%	0.0	99.43%
C1	Raw culture, NI	*Sulfitobacter* sp.	99%	0.0	99.57%
C2	FC, NNI	*Roseovarius nubinhibens*	99%	0.0	99.31%
C3	FC, NNI	*Phaeobacter piscinae*	99%	0.0	99.43%
C5	FC, NNI	*Roseovarius nubinhibens*	100%	0.0	99.37%
C6	FC, NNI	*Sulfitobacter* sp. LZD014	100%	0.0	98.86%
C7	FC, NNI	*Roseovarius nubinhibens*	100%	0.0	99.62%
C8	FC, NNI	*Alteromonas tagae*	99%	0.0	97.35%
C9	FC, NNI	*Sulfitobacter pacificus*	99%	0.0	99.24%
D1	FC, NNI	*Sulfitobacter* sp. LZD014	99%	0.0	99.52%

D2	FC, NNI	*Halomonas alkaliphila*	99%	0.0	98.89%
D3	FC, NNI	*Sulfitobacter* sp.	99%	0.0	97.53%
D4	FC, NNI	*Phaeobacter piscinae*	99%	0.0	99.14%
D5	FC, NNI	*Alteromonas* sp.	98%	0.0	98.10%
D6	FC, NI	*Phaeobacter piscinae*	100%	0.0	99.24%
E2	FC, NI	*Alteromonas macleodii*	99%	0.0	99.14%
E3	FC, NI	*Phaeobacter piscinae*	99%	0.0	99.05%
E4	FC, NI	*Phaeobacter piscinae*	100%	0.0	99.42%
E5	FC, NI	*Sulfitobacter* sp. LZD014	100%	0.0	99.33%
E6	FC, NI	*Phaeobacter* sp. M8-4.3	99%	0.0	98.24%
E7	FC, NI	*Sulfitobacter* sp. LZD014	99%	0.0	99.23%
E8	FC, NI	*Phaeobacter piscinae*	100%	0.0	99.42%
E9	FC, NI	*Phaeobacter piscinae*	100%	0.0	98.90%
F1	FC, NI	*Sulfitobacter* sp.	100%	0.0	98.82%
F2	FC, NI	*Vibrio anguillarum*	100%	0.0	97.43%
F3	FC, NI	*Phaeobacter* sp. M8-4.3	99%	0.0	98.07%
F4	FC, NI	*Sulfitobacter* sp.	94%	0.0	96.22%
F5	FM, NNI	*Vibrio* sp.	100%	0.0	98.70%
F6	FM, NNI	*Phaeobacter piscinae*	100%	0.0	98.72%
F7	FM, NNI	*Sulfitobacter* sp.	99%	0.0	99.33%
F8	FM, NNI	*Roseovarius nubinhibens*	99%	0.0	99.44%
F9	FM, NNI	*Roseovarius nubinhibens*	99%	0.0	99.71%
G1	FM, NNI	*Sulfitobacter* sp.	99%	0.0	99.43%
G2	FM, NNI	*Phaeobacter piscinae*	100%	0.0	99.23%
G3	FM, NNI	*Alteromonas* sp.	97%	0.0	97.75%
G5	FM, NNI	*Roseovarius nubinhibens*	100%	0.0	98.91%
G7	FM, NNI	*Vibrio* sp.	99%	0.0	97.46%
G8	FM, NNI	*Roseovarius nubinhibens*	99%	0.0	99.05%
H1	FM, NI	*Sulfitobacter* sp. LZD014	99%	0.0	99.61%
H2	FM, NI	*Phaeobacter piscinae*	100%	0.0	98.96%
H3	FM, NI	*Phaeobacter piscinae*	99%	0.0	99.33%
H4	FM, NI	*Phaeobacter* sp. M8-4.3	99%	0.0	98.33%
H8	FM, NI	*Phaeobacter piscinae*	99%	0.0	99.33%
H9	FM, NI	*Alteromonas macleodii*	100%	0.0	91.23%

I1	FM, NI	*Phaeobacter piscinae*	100%	0.0	99.14%
I2	FM, NI	*Phaeobacter piscinae*	99%	0.0	99.04%
I3	FM, NI	*Phaeobacter piscinae*	100%	0.0	99.24%
I4	Raw culture, NI	*Phaeobacter piscinae*	99%	0.0	98.94%

Figure S1. Inhibition assay by *Isochrysis galbana* (left) and *Tetraselmis suecica* (right) microbiomes against *Vibrio anguillarum* NB10_gfp, at a starting concentration of 3.1 ± 0.3 log CFU mL^{-1}, as measured by absorbance at 600 nm. The inhibitory effect of serial dilutions (10^{-1} (△), 10^{-2} (●), 10^{-3} (□), 10^{-4} (▲), 10^{-5} (○)) of different fractions of the algal cultures have been tested: full culture (FC; S1A and S1D), with algal and bacterial cells; filtered microbiome (FM; S1B and S1E), where algal cells have been removed; and axenic (AX; S1C and S1F) cultures, where the algae cells are free of bacteria.

954 **Figure S2.** Native microbiome composition (top 10 most abundant genera) of two *Isochrysis galbana* cultures of different age based on the 16S rRNA amplicon

955 sequencing results. One culture, NNI, has been newly provided by an aquaculture facility and has a relatively freshly recruited microbiome (left). The other

956 culture, NI has been regularly subcultured under laboratory conditions for almost four years (right).

960 **Figure S3.** Inhibition of *Vibrio anguillarum* NB10_gfp by 64 isolates from the *Isochrysis galbana*

961 microbiome.

962